IDEAS home Printed from https://ideas.repec.org/r/eee/respol/v30y2001i4p535-588.html
   My bibliography  Save this item

The dynamics of technological innovation: the case of the pharmaceutical industry

Citations

Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
as


Cited by:

  1. Lockhart, Michelle & Babar, Zaheer Ud-Din & Garg, Sanjay, 2010. "Evaluation of policies to support drug development in New Zealand," Health Policy, Elsevier, vol. 96(2), pages 108-117, July.
  2. Angelo Kenneth S. Romasanta & Peter Sijde & Jacqueline Muijlwijk-Koezen, 2020. "Innovation in pharmaceutical R&D: mapping the research landscape," Scientometrics, Springer;Akadémiai Kiadó, vol. 125(3), pages 1801-1832, December.
  3. Desmond Sheridan & Jim Attridge, 2006. "The Impact of Therapeutic Reference Pricing on Innovation in Cardiovascular Medicine," PharmacoEconomics, Springer, vol. 24(2), pages 35-54, December.
  4. García-Alonso, María D.C. & Levine, Paul, 2008. "Strategic procurement, openness and market structure," International Journal of Industrial Organization, Elsevier, vol. 26(5), pages 1180-1190, September.
  5. Selma Regina MARTINS OLIVEIRA, 2019. "Relationship Between Technological Eco-Innovation Capacity And Innovation Performance: Evidence From Most Innovative Firms In The Usa," Proceedings of the INTERNATIONAL MANAGEMENT CONFERENCE, Faculty of Management, Academy of Economic Studies, Bucharest, Romania, vol. 13(1), pages 163-178, November.
  6. Fumio Teramae & Tomohiro Makino & Yeongjoo Lim & Shintaro Sengoku & Kota Kodama, 2020. "Impact of Research and Development Strategy on Sustainable Growth in Multinational Pharmaceutical Companies," Sustainability, MDPI, vol. 12(13), pages 1-15, July.
  7. Jan Ende & Wilfred Dolfsma, 2004. "Technology-push, demand-pull and the shaping of technological paradigms - Patterns in the development of computing technology," Journal of Evolutionary Economics, Springer, vol. 15(1), pages 83-99, January.
  8. Sternitzke, Christian, 2010. "Knowledge sources, patent protection, and commercialization of pharmaceutical innovations," Research Policy, Elsevier, vol. 39(6), pages 810-821, July.
  9. Michalski, Tomasz, 2012. "Input substitutability, trade costs and location," Economics Letters, Elsevier, vol. 117(1), pages 57-59.
  10. Grantham, Andrew & Tsekouras, George, 2005. "Diffusing wireless applications in a mobile world," Technology in Society, Elsevier, vol. 27(1), pages 85-104.
  11. Mulinari, Shai, 2015. "Divergence and convergence of commercial and scientific priorities in drug development: The case of Zelmid, the first SSRI antidepressant," Social Science & Medicine, Elsevier, vol. 138(C), pages 217-224.
  12. Vladimir Aleksandrovich Plotnikov & Svetlana Nikolaevna Pshenichnikova, 0. "Analysis of Dynamic Characteristics of the Economic Systems in the Region of the CIS," Administrative Consulting, Russian Presidential Academy of National Economy and Public Administration. North-West Institute of Management., issue 8.
  13. Ingo Stiller & Arjen Witteloostuijn & Bart Cambré, 2021. "Do current radical innovation measures actually measure radical drug innovation?," Scientometrics, Springer;Akadémiai Kiadó, vol. 126(2), pages 1049-1078, February.
  14. Shyama V. Ramani & Samira Guennif, 2012. "Catching up in the Pharmaceutical Sector: Lessons from Case Studies of India and Brazil," Chapters, in: Franco Malerba & Richard R. Nelson (ed.), Economic Development as a Learning Process, chapter 5, Edward Elgar Publishing.
  15. Ingo Stiller & Arjen Witteloostuijn & Bart Cambré, 2022. "Determinants of radical drug innovation: a systematic literature review," Management Review Quarterly, Springer, vol. 72(4), pages 967-1016, December.
  16. Jim Attridge, 2006. "Equity Of Access To Innovative Medicines: Mission Impossible?," Economic Affairs, Wiley Blackwell, vol. 26(3), pages 17-23, September.
  17. Sahaym, Arvin & Howard, Michael D. & Basu, Sandip & Boeker, Warren, 2016. "The parent's legacy: Firm founders and technological choice," Journal of Business Research, Elsevier, vol. 69(8), pages 2624-2633.
  18. Anna Giunta & Filippo M. Pericoli & Eleonora Pierucci, 2016. "University–Industry collaboration in the biopharmaceuticals: the Italian case," The Journal of Technology Transfer, Springer, vol. 41(4), pages 818-840, August.
  19. Fraenkel, Stefan & Haftor, Darek M. & Pashkevich, Natallia, 2016. "Salesforce management factors for successful new product launch," Journal of Business Research, Elsevier, vol. 69(11), pages 5053-5058.
  20. Seung In Um & Changone Kim & Taejin Ha & Jinju Kim & Heesang Lee, 2022. "Morphological Change and Internal Growth Factors of Firms in the Korean Pharmaceutical Industry in Recent Decades," Sustainability, MDPI, vol. 14(22), pages 1-19, November.
  21. Jorge Niosi, 2010. "Building National and Regional Innovation Systems," Books, Edward Elgar Publishing, number 14006.
  22. Huang, Shu-Chin, 2013. "Capital outflow and R&D investment in the parent firm," Research Policy, Elsevier, vol. 42(1), pages 245-260.
  23. Selma Regina Martins Oliveira & Roberto Sbragia, 2015. "Modelling to assess the impact of technological innovation capacity in the performance of high complexity environments," International Journal of Business Performance and Supply Chain Modelling, Inderscience Enterprises Ltd, vol. 7(1), pages 12-35.
  24. Samira Guennif & Shyama V. Ramani, 2010. "Catching up in pharmaceuticals: a comparative study of India and Brazil," CEPN Working Papers hal-00632439, HAL.
  25. Marcel Corstjens & Edouard Demeire & Ira Horowitz, 2005. "New-product success in the pharmaceutical industry: how many bites at the cherry?," Economics of Innovation and New Technology, Taylor & Francis Journals, vol. 14(4), pages 319-331.
  26. Santiago-Rodriguez, Fernando, 2008. "Facing the Trial of Internationalizing Clinical Trials to Developing Countries: Some Evidence from Mexico," MERIT Working Papers 2008-023, United Nations University - Maastricht Economic and Social Research Institute on Innovation and Technology (MERIT).
  27. Arup K. Sen, 2009. "Outsourcing Of Research And Development Activities: Evidence From U.S. Biopharmaceutical Firms," Global Journal of Business Research, The Institute for Business and Finance Research, vol. 3(1), pages 73-82.
  28. Enda Hannon, 2016. "Industrial policy and employment in the UK: evidence from the pharmaceutical sector," Industrial Relations Journal, Wiley Blackwell, vol. 47(1), pages 2-20, January.
  29. Becker, Markus C. & Lillemark, Morten, 2006. "Marketing/R&D integration in the pharmaceutical industry," Research Policy, Elsevier, vol. 35(1), pages 105-120, February.
  30. Claus Rerup, 2009. "Attentional Triangulation: Learning from Unexpected Rare Crises," Organization Science, INFORMS, vol. 20(5), pages 876-893, October.
  31. Smita Srinivas, 2023. "When is industry ‘sustainable’? The economics of institutional variety in a pandemic," Review of Evolutionary Political Economy, Springer, vol. 4(1), pages 75-107, April.
  32. Smoliński, Adam & Pichlak, Magdalena, 2009. "Innovation in Polish industry: The cluster concept applied to clean coal technologies in Silesia," Technology in Society, Elsevier, vol. 31(4), pages 356-364.
  33. Tassey, Gregory, 2005. "The disaggregated technology production function: A new model of university and corporate research," Research Policy, Elsevier, vol. 34(3), pages 287-303, April.
  34. Claudimar Pereira da Veiga & Cassia Rita Pereira da Veiga & Mônica Maier Giacomini & Heitor Takashi Kato & Jansen Maia Del Corso, 2015. "Evolution of Capabilities in the Discovery Cycle of an Innovation in the Pharmaceutical Market," International Review of Management and Marketing, Econjournals, vol. 5(3), pages 141-153.
  35. Lehrer, Mark & Nell, Phillip & Gärber, Lisa, 2009. "A national systems view of university entrepreneurialism: Inferences from comparison of the German and US experience," Research Policy, Elsevier, vol. 38(2), pages 268-280, March.
  36. Liping Fu & Fan Wu & Shan Zhang, 2022. "Evolutionary Path and Innovative Development of Pharmaceutical Industrial Cluster—A Case Study of Shijiazhuang, China," IJERPH, MDPI, vol. 19(5), pages 1-18, March.
  37. Zoltán Lakner & Anna Kiss & József Popp & Zoltán Zéman & Domicián Máté & Judit Oláh, 2019. "From Basic Research to Competitiveness: An Econometric Analysis of the Global Pharmaceutical Sector," Sustainability, MDPI, vol. 11(11), pages 1-17, June.
  38. Yuan Li & Yi Liu & Feng Ren, 2007. "Product innovation and process innovation in SOEs: evidence from the Chinese transition," The Journal of Technology Transfer, Springer, vol. 32(1), pages 63-85, April.
  39. Samira Guennif & Shyama V. Ramani, 2010. "Catching up in pharmaceuticals: a comparative study of India and Brazil," Working Papers hal-00632439, HAL.
  40. Gonzalez, Eduardo & Gascon, Fernando, 2004. "Sources of productivity growth in the Spanish pharmaceutical industry (1994-2000)," Research Policy, Elsevier, vol. 33(5), pages 735-745, July.
  41. Lee, Won Sang & Sohn, So Young, 2018. "Effects of standardization on the evolution of information and communications technology," Technological Forecasting and Social Change, Elsevier, vol. 132(C), pages 308-317.
  42. Srinivas, Smita, 2006. "Industrial Development and Innovation: Some Lessons from Vaccine Procurement," World Development, Elsevier, vol. 34(10), pages 1742-1764, October.
IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.